Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns

Evaluation and definition of response and progression from trials to clinical practice

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Latest in bladder cancer from the second half of 2025

Do all hormone sensitive prostate cancers need triplet therapy?

Panel Discussion: Case based discussions muscle invasive bladder cancer

Choosing Wisely for genitourinary cancers

ESMO 2025: Precision medicine in bladder cancer

ESMO 2025: Highlights and analysis

Best practice in precision medicine for prostate cancer